Arbutus to Join Two May 2024 Investor Conferences

Arbutus Biopharma Corporation, based in Warminster, Pennsylvania, and listed on Nasdaq as ABUS, is making strides in the field of biopharmaceuticals with a focus on curing chronic hepatitis B virus (cHBV) infections. This clinical-stage company leverages its deep understanding of virology to create novel therapeutic solutions aimed at providing a functional cure for cHBV.

The company's management team is set to participate in two significant investor conferences in New York. They will engage in one-on-one meetings and host discussions at both events. The first event is the Citizens JMP Life Sciences Conference, where Arbutus will feature in a fireside chat scheduled for May 14, 2024, at 9:30 am ET. The second event is the H.C. Wainwright 2nd Annual BioConnect Investor Conference, with another fireside chat set for May 20, 2024, at 3:30 pm ET. Those interested in viewing these discussions can access live webcasts through a link provided by the company, which will also host an archived replay of the webcasts on its website for a limited duration after the events.

Arbutus Biopharma Corporation aims to develop treatments with unique mechanisms of action that can be combined to achieve a functional cure for cHBV patients. The company's strategy to combat cHBV includes suppressing HBV DNA, reducing surface antigen levels, and boosting immune responses specific to HBV. Their proprietary pipeline features several internally developed compounds, including the RNA interference (RNAi) therapeutic imdusiran (AB-729) and the oral PD-L1 inhibitor AB-101.

Imdusiran has shown promising clinical results, particularly in reducing surface antigens and reactivating HBV-specific immune responses. Currently, it is being tested in three Phase 2a combination clinical trials. Meanwhile, AB-101 is undergoing evaluation in a Phase 1a/1b clinical trial, further contributing to Arbutus's comprehensive approach to developing a cure for chronic hepatitis B.

The company continues to focus on advancing its clinical programs and exploring new therapeutic combinations, aiming to make significant strides in the fight against cHBV. Their innovative approach and dedication to leveraging virology expertise position them as a notable player in the biopharmaceutical industry, committed to improving the lives of those affected by chronic hepatitis B.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!